Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.
The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.
We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.
Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.
Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.
As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.
At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.
Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.
Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Oppilotech develops first-in-class drugs. We believe that target selection is the most important decision we make in drug discovery – a selective high-quality molecule will never become a drug if it is modulating the wrong target. Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets. We undertake both the target selection and develop the drugs against the identified target. We initially focused our modelling efforts on E.coli identifying several first-in-class antibacterial drug targets and generated active chemical matter against them. The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (e.g. DNA Damage Response) and inflammation.
Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway. Everything we do is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.